Section 4 of 6
Clinical evidence
319 evidence topics · 39 sources
Study summaries
RINGSIDE part B
Objective
Part B primary objective: effect on disease progression
Part B secondary objectives: tumor response, quality of life, and safety
Efficacy, safety, and tolerability compared with placebo
Location and study date
Global conduct and completion of enrollment
Registry status and dates for the combined Part A, Part B, and open-label extension record
| Study characteristic | Quoted record |
|---|---|
| Overall status | “Active, not recruiting” |
| Study start (actual) | “2021-09-01” |
| Primary completion (actual) | “2025-12-03” |
| Study completion (estimated) | “2026-12” |
| Number of locations | “This study has 53 locations” |
Registry sites by country
European Union member states, start of trial, and end of recruitment
Study design
Double-blind, placebo-controlled, randomized phase 3 design with central imaging review
Registry design record
| Study characteristic | Quoted record |
|---|---|
| Official title | “RINGSIDE: A Phase 2/3, Randomized, Multicenter Study to Evaluate AL102 in Patients With Progressing Desmoid Tumors” |
| Study type | “Interventional” |
| Allocation | “Randomized” |
| Interventional model | “Parallel Assignment” |
| Masking | “Quadruple” |
| Protocol number | “AL-DES-01” |
| EU trial number | “2024-515909-26-00” |
Relationship between Part A dose finding and Part B
Eligibility criteria
Key eligibility criteria as presented for the primary analysis
Part B inclusion criteria in the registry record
Additional Part B inclusion criteria in the EU trial record
Exclusion criteria for Parts A and B in the registry record
Additional Part B exclusion criteria in the EU trial record
Open-label extension entry criteria
Treatment
Randomized treatment arms
| Arm | Quoted registry description |
|---|---|
| Part B AL102 | “AL102, recommended dose regimen from Part A, 1.2 mg daily” |
| Part B placebo | “Placebo to match recommended dose regimen from Part A” |
| Open-label extension | “AL102, recommended dose regimen from Part A, 1.2 mg daily” |
| Study drug | “AL102 is an inhibitor of gamma secretase-mediated Notch signaling.” |
Dose levels used for dose reduction
Prohibited prior desmoid tumor therapy before the first dose
Study outcomes
Rationale for using progression-free survival as the primary endpoint
Primary endpoint: progression-free survival by blinded independent central review per RECIST v1.1
Primary endpoint in the EU trial record
Design consistent with prior registrational trials
Precedent: progression-free survival as the primary end point of DeFi
“The DeFi (Desmoid Fibromatosis) trial was a phase 3, international, double-blind, randomized, placebo-controlled trial to determine the efficacy and safety of nirogacestat in patients 18 years of age or older with a histologically confirmed diagnosis of progressing desmoid tumors (defined as ≥20% progression according to the Response Evaluation Criteria in Solid Tumors [RECIST], version 1.1, within 12 months before screening).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The primary end point was progression-free survival, defined as the time from randomization until the date of imaging-based or clinical progression or death.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Both imaging-based and clinical progression were confirmed by blinded independent central review.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Precedent: progression-free survival as the major efficacy outcome in the nirogacestat label
Precedent: progression-free survival as the primary end point of the sorafenib phase 3 trial
Variable natural history and the need for a placebo control
“Interpretation of the data is challenging, given the unpredictable natural history of the condition. Desmoid tumors can show rapid growth followed by periods of stabilization, spontaneous regression, or subsequent growth phases.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In a phase 3 trial of sorafenib involving adults with desmoid tumors, progression-free survival was significantly longer with sorafenib than with placebo (P<0.001); however, 20% of the participants in the placebo group had an objective response, a finding that highlights the need for a placebo control in this population.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Limitations of RECIST and progression-free survival in desmoid tumors
“The dimension-based RECIST is currently employed within clinical trials” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Existing clinical trial endpoints such as the Response Evaluation Criteria in Solid Tumors (version 1.1) and progression-free survival are inadequate in capturing treatment efficacy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“These surrogate endpoints for overall survival may not be appropriate for a disease with low mortality and importantly fail to capture whether treatments truly improve symptoms and/or affect daily living.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Alpha-controlled key secondary endpoints
Key secondary endpoint: objective response rate by blinded independent central review per RECIST v1.1
Key secondary endpoint: tumor volume at Week 24 by T2-weighted MRI or CT
Rationale for volumetric and T2-weighted MRI assessment
“The retrospective study also highlighted that RECIST may underestimate efficacy and that a better criterion may be magnetic resonance imaging (MRI) T2-weighted signal intensity, an imaging biomarker that signifies a biologic transformation from a cellular tumor to a collagenous scar.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Exploratory imaging end points included a comparison of RECIST measurements with total tumor volume and MRI T2-weighted signal intensity in patients.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Tumor assessments by blinded independent central review in the primary analysis poster
Key secondary endpoint: GODDESS worst pain intensity at Week 12
GODDESS scoring and administration in RINGSIDE
Rationale for GODDESS as a disease-specific endpoint
“This study was designed to develop a novel clinical trial endpoint by capturing patient-reported outcomes (PROs).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This is the first disease-specific PRO instrument developed for desmoid tumors.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Exploratory patient-reported endpoints: GODDESS symptom scores and PROMIS Physical Function
Other Part B secondary endpoints in the registry record
Part B secondary end points in the EU trial record
Registry secondary outcome measures without Week 24 and Week 12 time points, February 2026, superseded in June 2026
Registry secondary outcome measures with PROMIS, EQ-5D, and Brief Pain Inventory, November 2024, superseded in May 2025
Statistical analysis description
Number of participants (Planned and analyzed)
Participants randomized in Part B
Participants analyzed for progression-free survival
Registry enrollment for the combined record
Part A enrollment within the combined registry record
Planned enrollment in the registry record, November 2024, superseded in May 2025
Description of analysis sets
Intention-to-treat population defined as all participants who received at least one dose
Hazard ratio model stratified by tumor location
Hierarchy of alpha-controlled and non-alpha-controlled endpoints
Patient-reported outcome analyses in the intention-to-treat population with mixed models for repeated measures
Descriptive analysis of RECIST diameters, tumor volume, and T2-weighted signal
Kaplan-Meier estimation of duration of response
Results
Participant disposition
Duration of exposure by arm
Treatment duration and absence of progressive disease with varegacestat
Baseline characteristics
Demographics, tumor characteristics, and prior therapy
| Characteristic, n (%) | Varegacestat (n=79) | Placebo (n=77) |
|---|---|---|
| Median age (range), years | “42.0 (18–66)” | “39.0 (20–69)” |
| Male | “26 (32.9)” | “29 (37.7)” |
| Female | “53 (67.1)” | “48 (62.3)” |
| Premenopausal | “36 (45.6)” | “38 (49.4)” |
| Target tumor location: extra-abdominal | “60 (75.9)” | “49 (63.6)” |
| Target tumor location: intra-abdominal | “19 (24.1)” | “28 (36.4)” |
| Medical history of FAP | “7 (8.9)” | “8 (10.4)” |
| Median target tumor size per RECIST (range), mm | “75.1 (18.0, 244.9)” | “84.8 (21.3, 666.3)” |
| Any prior therapy | “52 (65.8)” | “60 (77.9)” |
| Prior surgery | “24 (30.4)” | “33 (42.9)” |
| Prior radiation therapy | “8 (10.1)” | “12 (15.6)” |
| Prior systemic therapy | “43 (54.4)” | “46 (59.7)” |
| Prior systemic therapies: 0 lines | “36 (45.6)” | “31 (40.3)” |
| Prior systemic therapies: 1 line | “25 (31.6)” | “22 (28.6)” |
| Prior systemic therapies: 2 or more lines | “18 (22.8)” | “24 (31.2)” |
Premenopausal women as a proportion of female participants
| Characteristic | Varegacestat (n=79) | Placebo (n=77) |
|---|---|---|
| Premenopausal, n/N of female participants (%) | “36/53 (67.9)” | “38/48 (79.2)” |
Baseline symptom burden and physical function
Efficacy results
Primary endpoint: progression-free survival
RINGSIDE phase 3 trial outcomes table
| Outcome | VAR (n=79) | PBO (n=77) | HR (95% CI) or Difference; P value |
|---|---|---|---|
| Median PFS (95% CI), radiographic, months | “NE (NE, NE)” | “24.9 (13.8, NE)” | “0.16 (0.07, 0.38); P<0.0001” |
| Confirmed ORR, n (%) | “44 (55.7)” | “7 (9.1)” | “P<0.0001” |
| TV change (cm3) at Week 24, LS mean (SE) | “-109.6 (40.64)” | “122.8 (42.72)” | “-232.4 (57.39); P<0.0001” |
| WPI (pain) change at Week 12, LS mean (SE) | “-2.24 (0.27)” | “0.18 (0.27)” | “-2.42 (0.37); P<0.0001” |
| Median best % change in TV (not alpha-controlled) | “-83.4” | “11.3” |
Progression-free survival events and median, ASCO 2026 presentation
| Arm | No. of patients | No. of events | Median PFS (95% CI) (mo) |
|---|---|---|---|
| Varegacestat | “79” | “7” | “NE (NE, NE)” |
| Placebo | “77” | “29” | “24.87 (13.80, NE)” |
Progression-free survival hazard ratio with confidence limits to three decimal places
Landmark progression-free survival rates at 1 and 2 years
| Arm | 1 Year | 2 Years |
|---|---|---|
| Varegacestat | “94% (95% CI: 85–98%)” | “89% (95% CI: 78–95%)” |
| Placebo | “66% (95% CI: 52–76%)” | “57% (95% CI: 43–69%)” |
Progression-free survival subgroups
Key secondary endpoint: confirmed objective response rate and complete responses
Objective response, time to response, and best overall response
| Outcome | Varegacestat (n=79) | Placebo (n=77) |
|---|---|---|
| Objective response rate, n (%) [95% CI] | “44 (55.7) [44.1, 66.9]” | “7 (9.1) [3.7, 17.8]” |
| Time to objective response (months), median (range) | “8.2 (2.6–28.0)” | “16.7 (8.1–30.2)” |
| Duration of response (months), median (95% CI), Kaplan-Meier estimate | “NE (NE, NE)” | “NE (NE, NE)” |
| Complete response (CR) | “3 (3.8)” | “1 (1.3)” |
| Partial response (PR) | “41 (51.9)” | “6 (7.8)” |
| Stable disease (SD) | “32 (40.5)” | “59 (76.6)” |
| Progressive disease (PD) | “0” | “10 (13.0)” |
| Not available | “3 (3.8)” | “1 (1.3)” |
Key secondary endpoint: change in tumor volume at Week 24
“Varegacestat: -109.6 (40.64)” (opens the source at this quote in a new tab)
“Placebo +122.8 (42.72)” (opens the source at this quote in a new tab)
“Difference: −232.4 (57.39), P<0.0001” (opens the source at this quote in a new tab)
“Least-squares mean (standard error)” (opens the source at this quote in a new tab)
Tumor volume measured by T2-weighted MRI or CT
Median best percent change in tumor volume
T2-weighted MRI signal intensity: descriptive analysis
Health-related quality of life and patient-reported outcomes
Key secondary endpoint: GODDESS worst pain intensity at Week 12
Exploratory PRO endpoints: GODDESS and PROMIS Physical Function 10a
GODDESS DTSS pain domain score: least-squares mean difference by week
| Analysis visit | Varegacestat participants with data | Placebo participants with data | Difference, varegacestat vs placebo |
|---|---|---|---|
| Week 12 | “52” | “55” | “Diff: -2.32” |
| Week 24 | “47” | “43” | “Diff: -2.02” |
| Week 48 | “37” | “27” | “Diff: -2.70” |
GODDESS DTSS TSS-5 symptom score: least-squares mean difference by week
| Analysis visit | Varegacestat participants with data | Placebo participants with data | Difference, varegacestat vs placebo |
|---|---|---|---|
| Week 12 | “52” | “55” | “Diff: -1.46” |
| Week 24 | “47” | “43” | “Diff: -1.43” |
| Week 48 | “37” | “27” | “Diff: -2.09” |
GODDESS TSS-5 symptom score at week 48, ESMO 2026 press release
PROMIS Physical Function 10a T-score: least-squares mean difference by week
| Analysis visit | Varegacestat participants with data | Placebo participants with data | Difference, varegacestat vs placebo |
|---|---|---|---|
| Week 12 | “54” | “60” | “Diff: +3.13” |
| Week 24 | “47” | “45” | “Diff: +5.84” |
| Week 48 | “37” | “26” | “Diff: +6.54” |
PROMIS Physical Function at week 48, ESMO 2026 press release
Safety results
Overall adverse event summary, ASCO 2026 abstract
Adverse events reported in 25% or more of either arm, ASCO 2026 presentation
| Adverse event (MedDRA preferred term), n (%) | Varegacestat any grade | Varegacestat grade 3+ | Placebo any grade | Placebo grade 3+ |
|---|---|---|---|---|
| Any adverse event | “79 (100)” | “45 (57)” | “70 (91)” | “13 (17)” |
| Diarrhea | “65 (82)” | “8 (10.1)” | “21 (27)” | “0” |
| Fatigue | “35 (44)” | “1 (1.3)” | “18 (23)” | “2 (2.6)” |
| Rash | “34 (43)” | “2 (2.5)” | “9 (12)” | “0” |
| Nausea | “28 (35)” | “0” | “20 (26)” | “0” |
| Cough | “27 (34)” | “0” | “4 (5)” | “0” |
| Hypophosphatemia | “27 (34)” | “1 (1.3)” | “2 (3)” | “0” |
| Alopecia | “26 (33)” | “0” | “3 (4)” | “0” |
| Dry mouth | “24 (30)” | “0” | “5 (7)” | “0” |
| Hair color changes | “20 (25)” | “0” | “0” | “0” |
| Pruritus | “20 (25)” | “0” | “4 (5)” | “0” |
| Rash maculo-papular | “20 (25)” | “1 (1.3)” | “1 (1)” | “0” |
Most common treatment-emergent adverse events reported in 20% or more of either arm, ESMO 2026 safety poster
| Adverse event (MedDRA preferred term), n (%) | Varegacestat any grade | Varegacestat grade ≥3 | Placebo any grade | Placebo grade ≥3 |
|---|---|---|---|---|
| Any adverse event | “79 (100)” | “45 (57)” | “70 (91)” | “13 (17)” |
| Diarrhea | “65 (82)” | “8 (10)” | “21 (27)” | “0” |
| Fatigue | “35 (44)” | “1 (1)” | “18 (23)” | “2 (2.6)” |
| Rash | “34 (43)” | “2 (3)” | “9 (12)” | “0” |
| Nausea | “28 (35)” | “0” | “20 (26)” | “0” |
| Cough | “27 (34)” | “0” | “4 (5)” | “0” |
| Hypophosphatemia | “27 (34)” | “1 (1)” | “2 (3)” | “0” |
| Alopecia | “26 (33)” | “0” | “3 (4)” | “0” |
| Dry mouth | “24 (30)” | “0” | “5 (7)” | “0” |
| Hair color changes | “20 (25)” | “0” | “0” | “0” |
| Pruritus | “20 (25)” | “0” | “4 (5)” | “0” |
| Rash maculo-papular | “20 (25)” | “1 (1)” | “1 (1)” | “0” |
| ALT increase | “18 (23)” | “3 (4)” | “4 (5)” | “0” |
| AST increase | “18 (23)” | “2 (3)” | “2 (3)” | “0” |
| Amenorrhea | “17 (22)” | “0” | “2 (3)” | “0” |
| Upper respiratory tract infection | “17 (22)” | “0” | “5 (7)” | “0” |
| Vomiting | “16 (20)” | “0” | “6 (8)” | “0” |
Frequently reported adverse events as grouped terms, with median time to first onset
| Adverse event, n (%) | Varegacestat all grades | Varegacestat median time to onset (days) | Varegacestat grade ≥3 | Placebo all grades | Placebo median time to onset (days) | Placebo grade ≥3 |
|---|---|---|---|---|---|---|
| Diarrhea | “65 (82.3)” | “14.0” | “8 (10.1)” | “21 (27.3)” | “21.0” | “0” |
| Rash (grouped term) | “56 (70.9)” | “24.0” | “4 (5.1)” | “13 (16.9)” | “69.0” | “0” |
| Fatigue (grouped term) | “46 (58.2)” | “27.5” | “1 (1.3)” | “24 (31.2)” | “19.0” | “2 (2.6)” |
| Hair follicle AEs (grouped term) | “32 (40.5)” | “59.0” | “2 (2.5)” | “3 (3.9)” | “70.0” | “0” |
| Cough (grouped term) | “31 (39.2)” | “16.0” | “1 (1.3)” | “5 (6.5)” | “198.0” | “0” |
| Nausea | “28 (35.4)” | “8.0” | “0” | “20 (26.0)” | “7.5” | “0” |
| Hypophosphatemia | “27 (34.2)” | “29.0” | “1 (1.3)” | “2 (2.6)” | “49.5” | “0” |
| Upper respiratory infection (grouped term) | “27 (34.2)” | “46.0” | “0” | “6 (7.8)” | “136.5” | “0” |
| Dry mouth | “24 (30.4)” | “13.0” | “0” | “5 (6.5)” | “8.0” | “0” |
| Hair color changes | “20 (25.3)” | “60.5” | “0” | “0” | “0” | |
| Ovarian toxicity (grouped term; percentage of the whole population) | “20 (25.3)” | “56.5” | “0” | “2 (2.6)” | “41.5” | “0” |
Select adverse events of interest by grade, including squamous cell carcinoma and keratoacanthoma
| Adverse event of interest | Varegacestat grade 1 | Varegacestat grade 2 | Varegacestat grade 3 | Placebo grade 1 | Placebo grade 2 | Placebo grade 3 |
|---|---|---|---|---|---|---|
| Diarrhea | “43.0%” | “29.1%” | “10.1%” | “23.4%” | “3.9%” | |
| Rash (grouped terms) | “36.7%” | “29.1%” | “5.1%” | “14.3%” | “2.6%” | |
| Ovarian toxicity | “25.3%” | “2.6%” | ||||
| Squamous cell carcinoma and keratoacanthoma | “1.3%” | “6.3%” | “1.3%” | “1.3%” | ||
| Elevated liver enzymes (ALT or AST grade 2 or higher) | “3.8%” | “3.8%” | “2.6%” |
Serious adverse events and deaths
Alopecia by grade
Dose levels and time to first dose reduction or interruption
“1.2 mg once daily” (opens the source at this quote in a new tab)
“0.9 mg once daily” (opens the source at this quote in a new tab)
“0.6 mg once daily” (opens the source at this quote in a new tab)
| Measure | Varegacestat | Placebo |
|---|---|---|
| Median time to first dose reduction to 0.9 mg | “to 0.9 mg (n=60): 3.7 (IQR 1.8, 8.3) months” | “to 0.9 mg (n=7): 5.6 (IQR 2.1, 16.1) months” |
| Median time to first dose reduction to 0.6 mg | “to 0.6 mg (n=36): 7.3 (IQR 3.0, 12.5) months” | “to 0.6 mg (n=2): 10.7 (IQR 4.9, 16.6) months” |
| Median time to first dose interruption | “Varegacestat (n=63): 2.5 (IQR 1.0, 5.7) months” | “Placebo (n=29): 3.4 (IQR 1.9, 7.3) months” |
Adverse events leading to dose reduction
Adverse events leading to dose interruption
Adverse events leading to discontinuation
Ovarian toxicity in premenopausal women
“A known class effect of GSI” (opens the source at this quote in a new tab)
“Varegacestat 56% | Placebo 5%” (opens the source at this quote in a new tab)
“Resolved in 55% of those who reported it” (opens the source at this quote in a new tab)
“No discontinuations for ovarian toxicity” (opens the source at this quote in a new tab)
Ovarian toxicity resolution by treatment disposition
“8 off varegacestat, follow-up available” (opens the source at this quote in a new tab)
“OT resolved in 8 (100%)” (opens the source at this quote in a new tab)
“10 ongoing varegacestat” (opens the source at this quote in a new tab)
“OT resolved in 3 (30%)” (opens the source at this quote in a new tab)
“OT unresolved in 7 (70%)” (opens the source at this quote in a new tab)
“2 off study, no follow-up available” (opens the source at this quote in a new tab)
Most common adverse events by arm, rounded to whole percentages
Study limitations
Summary
- Part B results are available only as an ASCO 2026 meeting abstract and oral presentation, ESMO 2026 presentations, and Immunome press releases and investor presentations. The abstract states that it “does not include a full text component”. The ClinicalTrials.gov record (primary completion December 3, 2025; status active, not recruiting) lists no posted results, and no registry protocol or statistical analysis plan is available for comparison with the reported analyses. The study was “sponsored/funded by Immunome and Ayala Pharmaceuticals, Inc.”.
- The comparator is placebo. No trial has compared varegacestat with nirogacestat, the approved gamma secretase inhibitor; Immunome's cross-trial response rate chart states that “no head-to-head clinical trial has been conducted”.
- Crossover to the open-label extension was allowed from either arm at progression, and the open-label extension is ongoing. Median exposure was 20.3 months with varegacestat and 11.1 months with placebo, so cumulative adverse event frequencies are compared over unequal exposure.
- At the October 7, 2025 data cutoff, 7 of 79 varegacestat participants and 29 of 77 placebo participants had a PFS event; median PFS was not estimable and median duration of response was not reached with varegacestat, which limits the precision of the hazard ratio and of the 2-year landmark estimates.
- The ASCO presentation labels a “Post-hoc subgroup analysis to evaluate patients with poor prognosis”; the subgroups shown include age 30 years or younger, CTNNB1 mutation, and baseline tumor size above 10 cm, and the abstract states only that PFS “consistently favored VAR in all subgroups analyzed”.
- Baseline imbalances include intra-abdominal target tumors (24.1% with varegacestat and 36.4% with placebo), any prior therapy (65.8% and 77.9%), and prior surgery (30.4% and 42.9%); the placebo arm's target tumor size range extends to 666.3 mm.
- Dose reductions due to adverse events occurred in 80% of varegacestat participants (to 0.9 mg in 60 and to 0.6 mg in 36), and dose interruptions in 65%. The efficacy results therefore reflect a 1.2 mg starting dose with frequent reduction, and the dose intensity actually delivered has not been reported.
- The symptom, pain domain, and physical function analyses are exploratory, with nominal p values. Completion declined over time: at week 48, pain and symptom data were available for 37 varegacestat and 27 placebo participants, against 52 and 55 at week 12. The PROMIS Physical Function baseline was “redefined post hoc”. Characteristic adverse events (diarrhea in 82% versus 27%, alopecia in 33% versus 4%, hair color changes in 25% versus 0%) may have allowed participants to infer their assignment, which could bias patient-reported outcomes in a double-blind trial.
- Figures differ between sources. The PFS hazard ratio's 95% CI is 0.07 to 0.38 in the abstract and slides and 0.071 to 0.375 in Immunome releases. ORR is 55.7% versus 9.1% in the abstract and slides and 56% versus 9% in releases. Placebo discontinuation due to adverse events is 7% in the abstract, ASCO slides, and safety poster and 6% in the primary results poster. Premenopausal women are 45.6% of the varegacestat arm in one table and 67.9% of its female participants in another. Rash is 43% as a preferred term and 70.9% as a grouped term. Death is reported as “No deaths due to adverse events” in the ESMO safety poster and as “There were no deaths on study” in the investor presentations. Ovarian toxicity resolved in 55% overall but in all 8 participants with follow-up off treatment. Week 48 PROMIS Physical Function is reported as +3.90 versus −3.04 in the ESMO press release, while the presentation, using the redefined baseline, reports a difference of +6.54.
RINGSIDE part A
Objective
Study purpose: safety, preliminary efficacy, and selection of the phase III dose regimen
Post hoc analysis objective: treatment response in key subgroups
Exploratory analysis objective: T2-weighted signal intensity, tumor volume, and exposure-response
Location and study date
Screening and enrollment from October 2021 to July 2022 at 21 academic medical centers in seven countries
Transition to the open-label extension from October 2022 to May 2023 and data as of January 6, 2025
Study start and data cutoff
Enrollment completed as of March 2022 and interim data as of January 3, 2023
Registry dates and study identifier
| Field | Quoted record |
|---|---|
| First posted | “2021-05-04” |
| Study start (actual) | “2021-09-01” |
| Other study ID | “AL-DES-01” |
Study design
Open-label, randomized, dose-finding phase II part of a phase II/III trial
Registry design: Part A dose regimen finding and Part B placebo-controlled study
Dose selection after the last week 16 MRI and entry into the open-label extension
MRI schedule in the phase 2 part and the open-label extension
Transition to the open-label extension between week 36 and week 76
Eligibility criteria
Inclusion criteria: adults with histologically confirmed, progressing desmoid tumors
Registry inclusion criteria for Part A
Registry exclusion criteria for Parts A and B: cardiac, laboratory, and prior treatment
Open-label extension inclusion and exclusion criteria
Treatment
Randomization 1:1:1 to 1.2 mg once daily, 2 mg intermittent, or 4 mg intermittent
Treatment duration and switch to 1.2 mg once daily in the open-label extension
Registry arms of Part A and the open-label extension
Dose regimens: 2 mg and 4 mg on two days each week or 1.2 mg daily
Study outcomes
Rationale for using treatment-emergent adverse events as the primary endpoint
Primary endpoint: safety based on treatment-emergent adverse events
Registry primary outcome: frequency and severity of TEAEs and SAEs
Rationale: dose selection on safety and tolerability in a dose-finding study
Adverse events of special interest: ovarian toxicity, liver enzyme elevations, and nonmelanoma skin cancers
Secondary endpoint: change in tumor volume from baseline to week 16 by BICR
Rationale for volumetric MRI assessment
Exploratory endpoints: RECIST v1.1 objective response rate, duration of response, and MRI signal biomarkers
Rationale for T2-weighted signal intensity as a marker of tumor cellularity
Primary, secondary, and exploratory endpoints
Open-label extension endpoints in the registry
Statistical analysis description
Number of participants (Planned and analyzed)
Sample size: 12 participants per dose regimen for 85% power
Participants enrolled, MRI-evaluable, and entering the open-label extension
Registry enrollment
| Field | Quoted record |
|---|---|
| Enrollment (actual) | “198” |
Evaluable population of 36 participants
Interim evaluable populations by dose regimen
Description of analysis sets
Analysis of covariance of tumor volume change and confidence intervals for response
Evaluable population: at least one post-baseline scan
Subgroup analysis set: subgroups with at least 5 participants, pooled across dose regimens
Post hoc imaging analysis methods
Results
Participant disposition
Screening, enrollment, and discontinuation during the randomized trial
Exposure by dose arm during the randomized trial
Open-label extension: 29 participants and 12 remaining on treatment as of January 6, 2025
Time on treatment as of April 10, 2024: median 25.4 months
Time on treatment as of April 10, 2024: median 23.1 months
Baseline characteristics
Age, sex, mutation status, and prior therapy
Demographic and clinical characteristics by dose arm
| Characteristic | 1.2 mg once daily (n = 14) | 2 mg intermittent (n = 14) | 4 mg intermittent (n = 14) | All doses (N = 42) |
|---|---|---|---|---|
| Age, years, mean (SD) | “42.1 (11.32)” | “37.8 (14.76)” | “39.9 (13.99)” | “39.9 (13.23)” |
| Female, No. (%) | “11 (78.6)” | “9 (64.3)” | “11 (78.6)” | “31 (73.8)” |
| Women of childbearing potential, No. (%) | “9 (64.3)” | “7 (50.0)” | “7 (50.0)” | “23 (54.8)” |
| Intra-abdominal tumor at screening, No. (%) | “3 (21.4)” | “4 (28.6)” | “3 (21.4)” | “10 (23.8)” |
| Tumor volume at baseline by BICR, cm3, mean (SD) | “83.93 (92.280)” | “189.17 (368.846)” | “166.91 (211.038)” | “146.05 (242.664)” |
| CTNNB1 mutation, No. (%) | “8 (57.1)” | “4 (28.6)” | “8 (57.1)” | “20 (47.6)” |
| APC mutation, No. (%) | “2 (14.3)” | “5 (35.7)” | “2 (14.3)” | “9 (21.4)” |
| Prior systemic therapy, No. (%) | “9 (64.3)” | “13 (92.9)” | “7 (50.0)” | “29 (69.0)” |
| Prior surgery, No. (%) | “7 (50.0)” | “8 (57.1)” | “4 (28.6)” | “19 (45.2)” |
| Prior radiation therapy, No. (%) | “1 (7.1)” | “2 (14.3)” | “1 (7.1)” | “4 (9.5)” |
| Unidimensional tumor growth by ≥10% within 18 months of screening, No. (%) | “11 (78.6)” | “14 (100.0)” | “10 (71.4)” | “35 (83.3)” |
| Tumor-related pain not adequately controlled with nonopioid medicine, No. (%) | “5 (35.7)” | “5 (35.7)” | “5 (35.7)” | “15 (35.7)” |
Median age, performance status, and median baseline tumor volume
| Characteristic | 1.2 mg once daily (n=14) | All doses (N=42) |
|---|---|---|
| Age (years), median (min, max) | “44.0 (24, 61)” | “38.5 (19, 72)” |
| ECOG performance status 0, n (%) | “14 (100.0)” | “35 (83.3)” |
| ECOG performance status 1, n (%) | “0” | “7 (16.7)” |
| Intra-abdominal tumor at initial diagnosis, n (%) | “5 (35.7)” | “12 (28.6)” |
| Extra-abdominal tumor at initial diagnosis, n (%) | “9 (64.3)” | “30 (71.4)” |
| Tumor volume at baseline (cm3), median (min, max) | “46.30 (1.4, 244.9)” | “65.10 (1.4, 1270.3)” |
Efficacy results
Median best percent change by dose arm during the randomized trial
Tumor response by BICR per RECIST v1.1 during the randomized trial
| Response | 1.2 mg once daily (n = 14) | 2 mg intermittent (n = 14) | 4 mg intermittent (n = 14) | All doses (N = 42) |
|---|---|---|---|---|
| Partial response, No. (%) | “5 (35.7)” | “3 (21.4)” | “3 (21.4)” | “11 (26.2)” |
| Stable disease, No. (%) | “7 (50.0)” | “6 (42.9)” | “10 (71.4)” | “23 (54.8)” |
| Progressive disease, No. (%) | “0” | “2 (14.3)” | “0” | “2 (4.8)” |
| Not available, No. (%) | “2 (14.3)” | “3 (21.4)” | “1 (7.1)” | “6 (14.3)” |
| Objective response 95% CI | “12.8 to 64.9” | “4.7 to 50.8” | “4.7 to 50.8” | “13.9 to 42.0” |
| Time to objective response, weeks, median (min, max) | “30.00 (17.3, 40.9)” | “40.29 (38.3, 41.0)” | “51.00 (40.3, 53.7)” | “40.29 (17.3, 53.7)” |
Selection of 1.2 mg once daily for phase III
Pharmacokinetic exposure by dose regimen
Open-label extension: tumor volume, sum of diameters, and T2-weighted signal by original dose arm
Tumor response by BICR per RECIST v1.1 in the randomized trial and open-label extension combined
| Response | Original 1.2 mg once daily (n = 14) | Original 2 mg intermittent (n = 14) | Original 4 mg intermittent (n = 14) | All (N = 42) |
|---|---|---|---|---|
| Complete response, No. (%) | “0” | “1 (7.1)” | “1 (7.1)” | “2 (4.8)” |
| Partial response, No. (%) | “8 (57.1)” | “6 (42.9)” | “8 (57.1)” | “22 (52.4)” |
| Objective response, No. (%) | “8 (57.1)” | “7 (50.0)” | “9 (64.3)” | “24 (57.1)” |
| Objective response 95% CI | “28.9 to 82.3” | “23.0 to 77.0” | “35.1 to 87.2” | “41.0 to 72.3” |
| Time to objective response, weeks, median (min, max) | “37.71 (17.3, 65.1)” | “40.57 (28.1, 101.6)” | “63.00 (40.3, 121.3)” | “51.50 (17.3, 121.3)” |
| Duration of response, weeks, median (95% CI) | “NE (46.1 to NE)” | “NE (24.9 to NE)” | “NE (NE to NE)” | “NE (NE to NE)” |
Exploratory imaging analysis: correlations and week 16 changes
Exposure-response modeling: predicted median time to 30% tumor volume decrease of 3 months with 1.2 mg once daily
Objective response rate from 43% to 78% across subgroups
| Subgroup | Responders, No. (%) |
|---|---|
| Age ≤40 years (n=22) vs. >40 years (n=14) | “13 (59) vs. 10 (71)” |
| Tumor size <70 mm (n=18) vs. ≥70 mm (n=14) | “13 (72) vs. 9 (64)” |
| Prior lines of therapy: 0 (n=11), 1 (n=16), or 2+ (n=9) | “6 (55), 10 (63), 7 (78)” |
| Intra-abdominal (n=9) vs. extra-abdominal (n=27) | “4 (44) vs. 19 (70)” |
| APC (n=7) vs CTNNB1 (n=19) mutation | “3 (43) vs. 13 (68)” |
Objective response and duration of response by subgroup as of January 6, 2025
“Data cutoff: Jan. 6, 2025” (opens the source at this quote in a new tab)
“ORR by RECIST ranged from 50% to 78%” (opens the source at this quote in a new tab)
“Median DOR ranged from 37.1 to 79.8 weeks” (opens the source at this quote in a new tab)
“Responses were seen in all subgroups examined” (opens the source at this quote in a new tab)
| Subgroup | ORR, n (%) | DOR, weeks, median (min, max) |
|---|---|---|
| All MRI-evaluable patients (n=37) | “24 (65)” | “58.9 (12.1, 120.6)” |
| Age ≤40 years (n=22) | “13 (59)” | “66.1 (22.1, 110.0)” |
| Age >40 years (n=15) | “11 (73)” | “37.1 (12.1, 120.6)” |
| Tumor size <70 mm (n=19) | “10 (53)” | “52.1 (22.1, 99.0)” |
| Tumor size ≥70 mm (n=18) | “14 (78)” | “78.4 (12.1, 120.6)” |
| Prior lines of therapy 0 (n=11) | “6 (55)” | “79.8 (22.1, 95.9)” |
| Prior lines of therapy 1 (n=13) | “9 (69)” | “37.1 (12.1, 120.6)” |
| Prior lines of therapy 2+ (n=13) | “9 (69)” | “56.0 (12.1, 110.0)” |
| Intra-abdominal (n=10) | “5 (50)” | “46.1 (12.1, 99.0)” |
| Extra-abdominal (n=27) | “19 (70)” | “61.9 (12.1, 120.6)” |
| APC mutation (n=8) | “4 (50)” | “55.4 (12.1, 66.1)” |
| CTNNB1 mutation (n=19) | “13 (68)” | “79.6 (22.1, 120.6)” |
| CTNNB1 S45F (n=3) | “2 (67)” | “31.0 (24.9, 37.1)” |
| CTNNB1 T41A (n=5) | “2 (40)” | “88.2 (55.9, 120.6)” |
| CTNNB1 other (n=11) | “9 (82)” | “82.0 (22.1, 110.0)” |
Objective response and median best change in tumor volume in the evaluable population
| Response | 1.2 mg QD dose (n=12) | All doses (n=36) |
|---|---|---|
| Objective response rate (CR + PR), n (%) | “9 (75%)” | “23 (64%)” |
| Complete response, n (%) | “0 (0%)” | “2 (6%)” |
| Partial response, n (%) | “9 (75%)” | “21 (58%)” |
| Stable disease, n (%) | “3 (25%)” | “12 (33%)” |
| Progressive disease, n (%) | “0 (0%)” | “1 (3%)” |
| Disease control rate, n (%) | “12 (100%)” | “35 (97%)” |
Objective response in the evaluable and intention-to-treat populations
Interim partial response and tumor volume change at Week 16 and Week 28
Interim partial response and tumor volume change at Week 16 and Week 28, rounded values
Health-related quality of life and patient-reported outcomes
Patient-reported outcomes not analyzed because of limited data and small samples
Registered open-label extension GODDESS outcome measures
Safety results
Treatment-related adverse events: no grade 4 or 5 events and no treatment-related serious adverse events
Adverse events during the randomized trial: grade 3, serious, and most common events
Discontinuation because of adverse events by dose arm
Treatment-emergent adverse events during the randomized trial by dose arm
Adverse events of special interest: liver enzyme elevations, cutaneous squamous cell carcinoma, and ovarian toxicity
Adverse events of special interest by dose arm, appendix table
| Event, No. (%) | 1.2 mg once daily (n = 14) | 2 mg intermittent (n = 14) | 4 mg intermittent (n = 14) | All doses (N = 42) |
|---|---|---|---|---|
| One or more adverse events of special interest | “6 (42.9)” | “5 (35.7)” | “5 (35.7)” | “16 (38.1)” |
| Amenorrhea | “3 (21.4)” | “3 (21.4)” | “4 (28.6)” | “10 (23.8)” |
| Premature menopause | “0” | “0” | “1 (7.1)” | “1 (2.4)” |
| Elevated liver enzymes (CTCAE grade ≥2) | “2 (14.3)” | “2 (14.3)” | “0” | “4 (9.5)” |
| Squamous cell carcinoma of skin | “1 (7.1)” | “0” | “0” | “1 (2.4)” |
Open-label extension: five additional participants with treatment-related grade 3 adverse events
Treatment-emergent adverse events in the randomized trial and open-label extension combined
| Treatment-emergent adverse event, No. (%) | Original 1.2 mg once daily (n = 14) | Original 2 mg intermittent (n = 14) | Original 4 mg intermittent (n = 14) | All doses (N = 42) |
|---|---|---|---|---|
| Grade ≥3 | “6 (42.9)” | “11 (78.6)” | “6 (42.9)” | “23 (54.8)” |
| Treatment-related grade ≥3 | “4 (28.6)” | “6 (42.9)” | “4 (28.6)” | “14 (33.3)” |
| Serious | “1 (7.1)” | “6 (42.9)” | “1 (7.1)” | “8 (19.0)” |
| Leading to dose reduction | “7 (50.0)” | “3 (21.4)” | “8 (57.1)” | “18 (42.9)” |
| Leading to interruption | “11 (78.6)” | “8 (57.1)” | “9 (64.3)” | “28 (66.7)” |
| Leading to study drug withdrawal | “4 (28.6)” | “4 (28.6)” | “1 (7.1)” | “9 (21.4)” |
| Diarrhea | “14 (100.0)” | “9 (64.3)” | “12 (85.7)” | “35 (83.3)” |
| Nausea | “8 (57.1)” | “5 (35.7)” | “10 (71.4)” | “23 (54.8)” |
| Fatigue | “8 (57.1)” | “6 (42.9)” | “8 (57.1)” | “22 (52.4)” |
| Hypophosphatemia | “7 (50.0)” | “5 (35.7)” | “3 (21.4)” | “15 (35.7)” |
| Stomatitis | “7 (50.0)” | “5 (35.7)” | “3 (21.4)” | “15 (35.7)” |
| Cough | “3 (21.4)” | “5 (35.7)” | “6 (42.9)” | “14 (33.3)” |
| Rash | “1 (7.1)” | “7 (50.0)” | “6 (42.9)” | “14 (33.3)” |
| Upper respiratory tract infection | “3 (21.4)” | “2 (14.3)” | “6 (42.9)” | “11 (26.2)” |
Safety summary and grade 3 or higher adverse events as of January 6, 2025
“Data cutoff: Jan. 6, 2025” (opens the source at this quote in a new tab)
“8 pts (19%) had a serious adverse event (AE)” (opens the source at this quote in a new tab)
“9 pts (21%) discontinued due to an AE” (opens the source at this quote in a new tab)
“14 (33%) pts had treatment-related Grade 3 AEs” (opens the source at this quote in a new tab)
“No Grade 4-5 AEs” (opens the source at this quote in a new tab)
| Adverse event, n (%) | All grades (N=42) | Grade ≥3 (N=42) |
|---|---|---|
| Diarrhoea | “35 (83.3)” | “5 (11.9)” |
| Nausea | “23 (54.8)” | “0” |
| Fatigue | “22 (52.4)” | “2 (4.8)” |
| Hypophosphatemia | “15 (35.7)” | “0” |
| Stomatitis | “15 (35.7)” | “1 (2.4)” |
| Cough | “14 (33.3)” | “1 (2.4)” |
| Headache | “14 (33.3)” | “0” |
| Rash | “14 (33.3)” | “0” |
Updated safety: grade 3 drug-related TEAEs in 14 of 42 participants
Interim safety: grade 3 drug-related TEAEs in 26.2% of patients
Interim safety: grade 3 drug-related TEAE in 10 of 42 patients
Study limitations
Summary
- RINGSIDE Part A was an open-label, randomized, dose-finding phase II study with 14 participants in each of three varegacestat dose regimens and no placebo or active comparator arm; the investigators describe it as having “small sample sizes and no placebo or active comparator arm”. The primary endpoint was safety; change in tumor volume at week 16 by BICR was the secondary endpoint, and RECIST v1.1 objective response rate was exploratory.
- The sample size was powered for the change in tumor volume from baseline within each regimen (12 participants per regimen, 85% power), so comparisons between regimens are descriptive: the LS mean reduction at week 16 was statistically significant for 1.2 mg once daily (–39.8%) and not for the 2 mg (–21.7%) or 4 mg (–17.8%) intermittent regimens. The efficacy analysis set (37 MRI-evaluable participants, 88.1%) excluded participants without measurable disease at baseline or a valid MRI at week 4 or later.
- The open-label extension switched all 29 continuing participants (69.0%) to 1.2 mg once daily between week 36 and week 76, so long-term results by original dose arm (confirmed ORR 57.1%, 50.0%, and 64.3%) reflect both the randomized regimen and later exposure to 1.2 mg once daily. Participants could continue varegacestat after progression by BICR with sponsor approval.
- Response rates differ by data cutoff and analysis population: an evaluable-population ORR of 75% for 1.2 mg once daily and 64% for all doses (April 10, 2024), an intention-to-treat ORR of 55% for all doses in the 10-K, and a confirmed ORR of 57.1% among all 42 participants as of January 6, 2025. Two abstracts with the April 10, 2024 cutoff report different median times on treatment (25.4 and 23.1 months), and two interim abstracts report grade 3 drug-related TEAEs in 26.2% (January 3, 2023 cutoff) and in 10 of 42 participants (24%).
- Subgroup analyses were post hoc, pooled across dose regimens, and limited to subgroups with at least 5 participants; the investigators state that “The sample sizes in each subgroup are relatively small”. The T2-weighted signal and exposure-response analyses were exploratory.
- Patient-reported outcomes were not analyzed because of “limited data availability and small sample sizes”. Ovarian toxicity had not resolved at last follow-up in 6 of 12 affected women. The study was sponsored by Immunome and Ayala Pharmaceuticals.
Small sample sizes and no placebo or active comparator arm
Limitations of the post hoc subgroup analysis
CA002-001
Objective
Primary and secondary objectives
“The primary objective was to establish the safety, tolerability and Maximum Tolerated Dose (MTD) of BMS-986115.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The secondary objectives were to assess pharmacokinetics, pharmacodynamics and preliminary anti-tumour activity of BMS-986115.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Registry statement of purpose
Location and study date
Registry status, dates, and sites
| Study characteristic | Quoted record |
|---|---|
| Protocol number | “CA002-001” |
| Sponsor | “Bristol-Myers Squibb” |
| Overall status | “Terminated” |
| Reason stopped | “(Non-safety reason, business objectives have changed)” |
| Study start | “2013-11” |
| Primary completion | “2016-03” |
| Study completion | “2016-03” |
| United States site | “Usc/Norris Comprehensive Cancer Center” |
| Site cities | “Los Angeles”; “Parkville”; “Vancouver”; “Toronto” |
Study design
Open-label, multi-arm phase 1 dose escalation
“In this open label phase I dose escalation study, BMS-986115 was administered as an oral single agent on once daily continuous (QD) and two times weekly intermittent (BIW) schedules.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The study was an ascending multiple-dose Phase I study and conducted in accordance with the Declaration of Helsinki and International Conference on Harmonisation Good Clinical Practice Guidelines.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Arm A and Arm B were conducted in a sequential manner.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Accelerated titration followed by a 3 + 3 design
“The dose escalation phase was initially conducted using an accelerated titration design [18] in which a single subject was enrolled in each cohort, and was switched to a 3 + 3 design with modified Fibonacci dose escalation if any of the following occurred in a single-subject cohort: grade 2 treatment-related diarrhoea lasting >36 h despite appropriate medical management; or any other grade 2 treatment-related adverse advent (AE), excluding asymptomatic electrolyte abnormalities that were manageable with appropriate supplements, alopecia and fatigue lasting ≤5 days.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For single-subject cohorts, dose escalation occurred in increments of 100% above the previous dose.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Dose escalation continued until the MTD was established or until the sponsor and investigators concurred that further dose escalation was not warranted. Once MTD was established in a given study arm, approximately 6 additional subjects were to be treated in a dose expansion cohort, at a dose equal to or below the MTD.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Registry design fields
| Study characteristic | Quoted record |
|---|---|
| Phase | “Phase 1” |
| Allocation | “Non-Randomized” |
| Intervention model | “Parallel Assignment” |
| Masking | “None (Open Label)” |
| Primary purpose | “Treatment” |
| Arms | “Arm A: Dose Escalation (BMS-986115)”; “Arm A: Dose Expansion (BMS-986115)”; “Arm B: Dose Escalation (BMS-986115)”; “Arm B: Dose Expansion (BMS-986115)” |
Sponsor and population as described by Immunome
Eligibility criteria
Advanced solid tumours refractory to or relapsed from standard therapies
“Male and female subjects who were 18 years or older and had a histological or cytological diagnosis of advanced solid tumours refractory to or relapsed from standard therapies were eligible.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The inclusion criteria included life expectancy of ≥3 months, ECOG performance status 0–1, and adequate organ function including ECG parameters.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Subjects were required to have an adequate lipid profile as increases in triglycerides were seen in the multiple dose rat study with BMS-986115.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Main exclusion criteria
“The main exclusion criteria were: symptomatic or unstable brain metastases, any serious medical disorders including active infection and significant cardiovascular disease, major thromboembolic events or bleeding diathesis within 6 months of study entry, current or recent GI disease that increases the risk of diarrhoea, any major surgery or GI disorder that would interfere with administration of oral medications, conditions requiring chronic systemic glucocorticoid use, therapeutic anticoagulation, and concomitant second malignancies (except adequately treated in situ cancers and non-melanomatous skin cancers).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Prior exposure to BMS-986115 or other Notch inhibitors was not allowed and those with a history of allergy to Notch inhibitors including BMS-986115related compounds were excluded.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Washout and prohibited concomitant medications
“Patients required a washout period of at least 6 months for prior therapy with nucleoside analogues, 6 weeks for prior therapy with nitrosoureas, mitomycin C and liposomal doxorubicin and 4 weeks for other anticancer therapies.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The prohibited concomitant medications included herbal supplements, medications causing Torsades de Pointes, strong inhibitors or inducers of CYP3A4 or P-gp, and sensitive substrates of CYP3A4 with a narrow therapeutic window.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Registry criteria for gastrointestinal disease and hypertriglyceridemia
Treatment
Dose levels in the once-daily and twice-weekly arms
Cycle structure and dosing days
“In the treatment period, the first cycle was 7 days in duration, and all subsequent cycles were 28 days in duration. Subjects received a single dose of BMS-986115 on Cycle 1 Day 1. In Cycle 2 and all subsequent cycles, subjects in Arm A received QD doses of BMS-986115 (i.e., Day 1 to Day 28 inclusive) and subjects in Arm B received BIW doses of BMS-986115 (i.e., Days 1, 2, 8, 9, 15, 16, 22, and 23 of each cycle).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Dose interruption, dose reduction, and treatment duration
“Dose interruption (up to 28 days) and/or dose modification (up to 2 dose reductions) were permitted in the event of study drug toxicity. Subjects could continue to receive treatment in the study until they experienced disease progression, unacceptable AEs, or withdrew consent.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Study outcomes
Rationale for using maximum tolerated dose as the primary endpoint
Gastrointestinal toxicity as the dose-limiting effect of Notch inhibition
“In animal studies, the main pharmacological toxicities included dose-dependent gastrointestinal (GI) toxicity, lymphoid depletion, and interruption of ovarian follicle maturation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“As prolonged inhibition of the Notch pathway is associated with increased GI toxicity, an oral Notch inhibitor with a short half-life that allows transient rather than continuous target engagement is desirable.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The clinical development of Notch inhibitors has been hampered by on-target GI toxicity and most drugs have not been tolerable at daily continuous schedule [19–21].” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Dose-limiting toxicity period and definition
“DLT period was 35 days (from C1, duration of which was 7 days, to end of cycle 2, duration of which was 28 days).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Gr ≥3 diarrhoea lasting >24 h despite appropriate medical management; any other drug-related Gr ≥3 non-hematologic AE, except hyperlipidemia in subjects not receiving maximum medical management or electrolyte abnormalities that may be managed with supplements.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Registry primary outcome: safety and tolerability
Safety assessments
“Safety assessments consisted of physical examination, vital signs, weight, performance status assessment using ECOG (Eastern Cooperative Oncology Group) criteria and documentation of AEs and serious AEs (SAEs) for all treated subjects using the National Cancer Institute’s Common Toxicity Criteria for Adverse Events v4.03.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Secondary endpoint: pharmacokinetics of BMS-986115 and BMT-100948
“Pre and post treatment EDTA peripheral whole blood samples for the PK determination of BMS-986115 and its equally active metabolite BMT-100948 were collected on days 1 (pre-dose and 0.5, 1, 1.5, 2, 4, and 8 h post-dose), 2 (24 h post first dose), 3 (48 h post first dose), 4 (72 h post first dose) and 5 (120 h post first dose) of cycle 1 for both Arm A and Arm B” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Plasma concentrations of BMS-986115 and BMT-100948 were determined using a validated liquid chromatography-tandem mass spectrometry assay.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Secondary endpoint: Notch pathway gene expression as a pharmacodynamic biomarker
“Expression of Notch pathway-related genes in peripheral blood was measured as surrogate PD biomarkers for BMS-986115.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The level of inhibition of Hes1 and Deltex1 expression by oral doses of BMS-986115 in peripheral blood was measured as surrogate PD biomarkers.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Secondary endpoint: preliminary anti-tumour activity by RECIST 1.1
“Tumour assessments by CT or MRI were performed at baseline and approximately every 8 weeks during treatment, and at the end of treatment or 30-day follow-up if not done within the preceding 8 weeks. The radiological response to therapy was assessed using Response Evaluation Criteria in Solid Tumor (RECIST) 1.1.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Registry secondary outcome: investigator-assessed tumor response
Statistical analysis description
Number of participants (Planned and analyzed)
Planned participants per arm
Participants treated and evaluable for dose-limiting toxicity
“A total of 36 patients were treated in the study (24 in Arm A and 12 in Arm B).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Of 24 patients treated in Arm A, 20 patients were DLT evaluable for 5 QD dose levels evaluated (0.3 mg [N = 2], 0.6 mg [N = 2], 1.2 mg [N = 5], 1.5 mg [N = 6], and 2 mg [N = 5]) (Table 2).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Of 12 patients treated within Arm B, 10 were DLT evaluable for 3 BIW dose levels (2 mg [N = 2], 4 mg [N = 2], and 8 mg [N = 6]).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Participants treated per dose level
| Dose level | Total no. of patients | No. of DLT evaluable patients |
|---|---|---|
| Arm A, 0.3 mg once daily | “2”View highlighted excerpt for this quote | “2”View highlighted excerpt for this quote |
| Arm A, 0.6 mg once daily | “2”View highlighted excerpt for this quote | “2”View highlighted excerpt for this quote |
| Arm A, 1.2 mg once daily | “6”View highlighted excerpt for this quote | “5”View highlighted excerpt for this quote |
| Arm A, 1.5 mg once daily | “7”View highlighted excerpt for this quote | “6”View highlighted excerpt for this quote |
| Arm A, 2.0 mg once daily | “7”View highlighted excerpt for this quote | “5”View highlighted excerpt for this quote |
| Arm B, 2 mg twice weekly | “2”View highlighted excerpt for this quote | “2”View highlighted excerpt for this quote |
| Arm B, 4 mg twice weekly | “2”View highlighted excerpt for this quote | “2”View highlighted excerpt for this quote |
| Arm B, 8 mg twice weekly | “8”View highlighted excerpt for this quote | “6”View highlighted excerpt for this quote |
Description of analysis sets
Safety and pharmacokinetic populations
“All subjects who received at least one dose of BMS-986115 were evaluated for safety parameters.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Plasma concentration-time data for BMS-986115 and an equally active metabolite BMT-100948 were reported for subjects who received at least one dose of study medication. Non-compartmental analysis (NCA) was performed to characterize the PK parameters for the parent compound (BMS-986115) using nominal time.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Descriptive statistical analysis
“Demographics, baseline characteristics, safety and efficacy measurements were described using descriptive statistics. For PD analysis, geometric mean relative gene expression data for the Notch pathway genes Deltex1 and Hes1 were plotted.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Inclusion of CA002-001 participants in a pooled exposure-response safety analysis
Results
Participant disposition
Treatment until progression and discontinuation for adverse events
“Sixteen (67%) of the 24 subjects treated in Arm A and 6 (50%) of the 12 subjects treated in Arm B continued to receive treatment until disease progression. A total of 9 subjects discontinued treatment after experiencing one or more AEs that were either related to study drug (N = 5, 3 subjects in Arm A and 2 in Arm B) or not related to the study drug (N = 4, 2 subjects in each arm).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Duration of treatment
“The median duration of time on treatment was 5.6 weeks (range 0.9–57.9 weeks) for the overall study population, and was similar for subjects in Arm A (median 5.8 weeks, range 1.7–57.9 weeks) and those in Arm B (median 5.5 weeks, range 0.9–48.4 weeks).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Baseline characteristics
Demographics, performance status, cancer types, and prior therapy (N = 36)
One participant with desmoid fibromatosis
Efficacy results
Best tumour response and stable disease for more than 6 months
“Of the 36 treated subjects, 21 (58%) subjects had progressive disease and 11 (31%) had stable disease (SD) as a best tumour response and 4 were not evaluable. Of the 11 subjects with SD, 5 (1 clear cell renal cell carcinoma, 1 fibromatosis, 2 adenoid cystic carcinoma, and 1 retroperitoneal liposarcoma) had SD for more than 6 months (Supplementary Figure 1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Participant with fibromatosis treated at 1.5 mg once daily
“In addition, the patient with fibromatosis, who did not have documented disease progression before study entry, achieved SD with maximum disease shrinkage of 16.5% after ~9 months of treatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“All 3 patients who had prolonged SD with disease shrinkage were treated with the pharmacodynamically active doses of BMS-986115 (1.2 mg QD [renal cell carcinoma case], 1.5 mg QD [fibromatosis case], and 2 mg QD [retroperitoneal liposarcoma case]).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Participant with desmoid fibromatosis as described by Immunome
Pharmacokinetics: absorption, half-life, and accumulation
“BMS-986115 was rapidly absorbed following single/multiple-dose administration over the 0.3-mg to 8-mg dose range, and the median Tmax was within a range of 1 h to 3 h. There was a dose-related increase for both Cmax and AUCtau after BMS-986115 administration following single/multiple-dose administration over the 0.3-mg to 8-mg dose range. Following multiple once daily dose administration of BMS-986115, the median half-life ranged from 17.24 h to 28.01 h.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The median accumulation ratios (AUCtau ratio of Day 15/Day 1 values) of BMS-986115 after once daily dosing were 2.64, 3.9, 3.66, 2.33, and 2.19 for 0.3-, 0.6-, 1.2-, 1.5-, and 2-mg doses, respectively. Accumulation ratios (AUCtau ratio of Day 16/Day 1) of BMS-986115 after two consecutive days dosing in a week (Arm B) were 2.47, 3.01, and 2.77 for 2-, 4- and 8-mg doses, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Pharmacokinetics: active metabolite BMT-100948
“Plasma concentrations of BMT-100948 were low relative to plasma concentrations of the parent drug (BMS-986115). Median Cmax% ratios for BMT-100948 to that of BMS-986115 after a single dose on Day 1 ranged from 5 to 13%, and after multiple doses on Day 15 ranged from 12 to 16%, respectively. Similarly, median AUCtau ratio for BMT-100948 to that of BMS-986115 after a single dose on Day 1 ranged from 14% - 22%, and after multiple doses on Day 15 ranged from 17% - 27%, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Pharmacodynamics: inhibition of Hes1 and Deltex1 expression
“After 2 weeks of dosing at the highest tolerated doses of 1.2 mg QD and 1.5 mg QD, geometric mean relative expression of Hes1 was continuously inhibited by >50% below baseline, with peak inhibition of >80% (Fig. 2). Similarly, geometric mean relative expression of Deltex1 was continuously inhibited by greater than 45% for the entire dosing interval, with peak inhibition of >60% (Fig. 2). At the highest tolerated dose level of 4 mg BIW, geometric mean relative expression of Hes1 was inhibited by >75% for at least 48 h of the weekly dosing cycle and Deltex1 was inhibited by greater than 50%.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
Maximum tolerated dose and dose-limiting toxicities in the once-daily arm
“Based on the incidence of DLT, the MTD for QD dosing of BMS-986115 was 1.5 mg QD. At this dose level, 1 DLT (Gr 3 nausea) was observed in one of 6 patients treated. No DLT was observed in 5 evaluable patients treated at 1.2 mg QD. The 2 mg QD dose was not tolerated with DLTs in 3 of the 5 DLT-evaluable patients (Gr 3 ileus; Gr 3 nausea; Gr 3 pruritus/urticaria).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Dose-limiting toxicities in the twice-weekly arm
“None of the two patients treated at 4 mg BIW had DLT. But, a higher dose of 8 mg BIW was not tolerated with DLTs in 2 of the 6 DLT-evaluable subjects (Gr 3 diarrhoea; Gr 3 nausea/dehydration/anorexia with Gr 2 fatigue).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Adverse events of any causality and treatment-related adverse events
“There were no treatment-related deaths. Adverse events (AE) were reported in all 36 (100%) subjects. The most frequently reported AEs (>50% of all treated subjects) regardless of causality were diarrhoea (72%), nausea (69%), hypophosphataemia (67%), fatigue (64%), decreased appetite (58%), and vomiting (53%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In the QD arm, a dose related trend was apparent in the frequency of GI events but this trend was not observed in the BIW arm (Table 3). The most common treatment-related Gr 3 or 4 AEs were hypophosphataemia (39%), diarrhoea (19%), nausea (11%), hypokalaemia (11%) and hyponatraemia (6%) (Table 4).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Treatment-related adverse events of all grades by dose level
Serious adverse events
“Overall, SAEs were reported for 18 (50%) subjects. Eight (6 in Arm A and 2 in Arm B) (22%) experienced SAEs that were treatment-related: Gr 3 diarrhoea (Arm B), Grade 3 diarrhoea with Gr 2 abdominal pain (Arm A), Gr 2 diarrhoea with Gr 2 dehydration (Arm A), Gr 3 nausea, dehydration and decreased appetite (Arm B), Gr 3 nausea with Gr 3 fatigue and Gr 4 hypophosphataemia (Arm A), Gr 3 colitis (Arm A), Gr 2 anaemia and Gr 3 pulmonary embolism (Arm A), and Gr 3 ileus (Arm A).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Discontinuation due to adverse events
“Nine subjects (25%) discontinued treatment due to AEs (Table 2), including 5 subjects who discontinued due to treatment-related diarrhoea with or without nausea (N = 3), dermatitis acneiform (N = 1), or dehydration and anorexia (N = 1). Four other subjects discontinued treatment due to non-treatment related AEs.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Grade 3 or 4 diarrhoea at the maximum tolerated dose
Study limitations
Summary
- CA002-001 was an open-label, nonrandomized phase 1 dose-escalation study without a comparator arm in 36 participants with advanced solid tumours (24 in the once-daily arm and 12 in the twice-weekly arm). One participant (3%) had desmoid fibromatosis, so the study provides no estimate of efficacy in desmoid tumors; that participant “did not have documented disease progression before study entry” and was treated at 1.5 mg once daily, a dose above the 1.2 mg once-daily dose used in RINGSIDE.
- Six participants received 1.2 mg once daily, and five of them were evaluable for dose-limiting toxicity. The median duration of treatment was 5.6 weeks (range 0.9 to 57.9 weeks), which limits the assessment of adverse events that emerge with longer exposure.
- The study was “terminated early for business reasons”, and the maximum tolerated dose of the twice-weekly schedule was not established. The registry lists the reason as a “Non-safety reason, business objectives have changed” and shows no posted results.
- Tumour response was assessed by the investigator per RECIST 1.1, with no central review reported. All analyses were descriptive.
- The eligibility criteria required ECOG performance status 0 to 1, and the baseline characteristics report one participant (3%) with baseline WHO performance status 2.
- Bristol-Myers Squibb sponsored and funded the study, and six authors were Bristol-Myers Squibb employees and stockholders.
Early termination limits conclusions
“Despite the demonstration of safety and tolerability, our study was terminated early for business reasons making it difficult to ultimately draw any firm conclusion.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“It is regrettable, however, that we did not manage to perform correlative analyses on tumors to identify potential biomarkers of response in these patients because of early termination of the study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
AL102-501
Objective
Effect of itraconazole on varegacestat pharmacokinetics in healthy participants
Location and study date
Registry status, dates, and site
| Study characteristic | Quoted record |
|---|---|
| Protocol number | “AL102-501” |
| Sponsor | “Immunome, Inc.” |
| Overall status | “Completed” |
| Study start (actual) | “2024-11-11” |
| Primary completion (actual) | “2024-12-30” |
| Study completion (actual) | “2025-05-07” |
| First posted | “2024-11-07” |
| Last update posted | “2025-05-11” |
| Site | “Celerion”; “Tempe” |
Study design
Open-label, fixed-sequence, two-period drug-drug interaction study
Registry design fields
| Study characteristic | Quoted record |
|---|---|
| Phase | “Phase 1” |
| Intervention model | “Single Group Assignment” |
| Masking | “None (Open Label)” |
| Primary purpose | “Other” |
| Keywords | “Drug-Drug Interaction”; “Pharmacokinetics” |
Eligibility criteria
Healthy adults aged 18 to 55 years
Exclusion criteria
Treatment
Single varegacestat dose alone and with itraconazole 200 mg
Study outcomes
Rationale for using pharmacokinetic parameters as the primary endpoint
Primary endpoints: varegacestat AUC, Cmax, and Tmax with and without itraconazole
Pharmacokinetic sampling for varegacestat and its metabolite
Secondary endpoints: safety, tolerability, and itraconazole trough concentrations
Strong CYP3A4 inhibitors prohibited in the first-in-human study
“The prohibited concomitant medications included herbal supplements, medications causing Torsades de Pointes, strong inhibitors or inducers of CYP3A4 or P-gp, and sensitive substrates of CYP3A4 with a narrow therapeutic window.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Statistical analysis description
Number of participants (Planned and analyzed)
Actual enrollment
| Study characteristic | Quoted record |
|---|---|
| Enrollment (actual) | “22” |
Description of analysis sets
No evidence found.
Results
Participant disposition
No evidence found.
Baseline characteristics
No evidence found.
Efficacy results
No evidence found.
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
No evidence found.
Study limitations
Summary
- AL102-501 is known only from its registry record. The record lists the study as “Completed”, with primary completion on 2024-12-30, and shows no posted results; no publication, congress presentation, or Immunome document reporting its results was identified, so the effect of itraconazole on varegacestat exposure is unknown from public sources.
- The study is an open-label, single-group, fixed-sequence design in 22 healthy participants aged 18 to 55 years, with women limited to those of non-childbearing potential. Each participant received a single dose of varegacestat alone and then with itraconazole, so the results apply to single-dose exposure in healthy adults.
- The registry record does not state the varegacestat dose given.
AL102-502
Objective
Effect of a single varegacestat dose on cardiac repolarization
Location and study date
Registry status, dates, and site
| Study characteristic | Quoted record |
|---|---|
| Protocol number | “AL102-502” |
| Sponsor | “Immunome, Inc.” |
| Overall status | “Completed” |
| Study start (actual) | “2025-02-24” |
| Primary completion (actual) | “2025-04-08” |
| Study completion (actual) | “2025-05-06” |
| First posted | “2025-03-03” |
| Last update posted | “2025-09-24” |
| Site | “Celerion”; “Tempe” |
Study design
Randomized, placebo- and moxifloxacin-controlled, three-way crossover
Registry design fields
| Study characteristic | Quoted record |
|---|---|
| Phase | “Phase 1” |
| Allocation | “Randomized” |
| Intervention model | “Crossover Assignment” |
| Masking | “This is a double-blind study (with respect to varegacestat and placebo only; moxifloxacin will be open label).” |
| Primary purpose | “Other” |
| Keyword | “thorough-QT” |
Eligibility criteria
Healthy adults aged 18 to 55 years
Exclusion criteria
Treatment
Single doses of varegacestat, placebo, and moxifloxacin 400 mg
Study outcomes
Rationale for using placebo-corrected QTc change as the primary endpoint
Primary endpoint: placebo-corrected QTc change and plasma concentrations
Delayed cardiac repolarization and torsade de pointes
Purpose of a thorough QT/QTc study and the threshold of regulatory concern
Positive control to establish assay sensitivity
Secondary endpoints: ECG parameters, pharmacokinetics, safety, and assay sensitivity
Statistical analysis description
Number of participants (Planned and analyzed)
Actual enrollment
| Study characteristic | Quoted record |
|---|---|
| Enrollment (actual) | “32” |
Description of analysis sets
No evidence found.
Results
Participant disposition
No evidence found.
Baseline characteristics
No evidence found.
Efficacy results
No evidence found.
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
No evidence found.
Study limitations
Summary
- AL102-502 is known only from its registry record. The record lists the study as “Completed”, with primary completion on 2025-04-08, and shows no posted results; no publication, congress presentation, or Immunome document reporting its results was identified, so the effect of varegacestat on the QTc interval is unknown from public sources.
- The study gave a single oral dose of varegacestat to 32 healthy participants aged 18 to 55 years, with women limited to those of non-childbearing potential. The registry record does not state the dose. In the phase 1 study of BMS-986115, the median accumulation ratio after once-daily dosing at 1.2 mg was 3.66, so exposure after a single dose is lower than exposure after 15 days of once-daily dosing.
- Moxifloxacin, the positive control, was given open label, and blinding applied to varegacestat and placebo only.
AL102-503
Objective
Pharmacokinetics, safety, and tolerability in hepatic impairment
Location and study date
Registry status, dates, and sites
| Study characteristic | Quoted record |
|---|---|
| Protocol number | “AL102-503” |
| Sponsor | “Immunome, Inc.” |
| Overall status | “Completed” |
| Study start (actual) | “2025-03-07” |
| Primary completion (actual) | “2025-11-05” |
| Study completion (actual) | “2026-03-06” |
| First posted | “2025-02-24” |
| Last update posted | “2026-03-10” |
| Sites | “Orlando Clinical Research Center”; “The Texas Liver Institute” |
Study design
Open-label, single-dose, parallel-group design with matched controls
Conditional enrollment of participants with severe hepatic impairment
Registry design fields
| Study characteristic | Quoted record |
|---|---|
| Phase | “Phase 1” |
| Intervention model | “Single Group Assignment” |
| Masking | “None (Open Label)” |
| Primary purpose | “Other” |
Eligibility criteria
Healthy matched participants aged 18 to 84 years
Treatment
Single oral dose of varegacestat on day 1
Study outcomes
Rationale for using pharmacokinetic parameters as the primary endpoint
Primary endpoints: AUC and Cmax of varegacestat and metabolite
Secondary endpoints: safety and tolerability
Statistical analysis description
Number of participants (Planned and analyzed)
Actual enrollment
| Study characteristic | Quoted record |
|---|---|
| Enrollment (actual) | “35” |
Description of analysis sets
No evidence found.
Results
Participant disposition
No evidence found.
Baseline characteristics
No evidence found.
Efficacy results
No evidence found.
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
No evidence found.
Study limitations
Summary
- AL102-503 is known only from its registry record. The record lists the study as “Completed”, with study completion on 2026-03-06, and shows no posted results; no publication, congress presentation, or Immunome document reporting its results was identified, so varegacestat exposure in hepatic impairment is unknown from public sources.
- The registry gives the actual enrollment as 35 participants but not their distribution across the healthy, mild, moderate, and severe hepatic impairment groups. Enrollment of the severe group (Child-Pugh C) was planned only “if appropriate”, contingent on data from the first three groups.
- The design is open label with a single oral dose, and the registry record does not state the dose.
AL102-504
Objective
Absorption, metabolism, excretion, and mass balance of carbon-14-labeled varegacestat
Location and study date
Registry status, dates, and site
| Study characteristic | Quoted record |
|---|---|
| Protocol number | “AL102-504” |
| Sponsor | “Immunome, Inc.” |
| Overall status | “Completed” |
| Study start (actual) | “2025-02-25” |
| Primary completion (actual) | “2025-03-11” |
| Study completion (actual) | “2025-03-26” |
| Last update posted | “2025-09-26” |
| Site | “Frontage Laboratories, Inc.”; “Secaucus” |
Study design
Single-center, open-label, single-dose radiolabel study
Registry design fields
| Study characteristic | Quoted record |
|---|---|
| Phase | “Phase 1” |
| Intervention model | “Single Group Assignment” |
| Masking | “None (Open Label)” |
| Primary purpose | “Other” |
Eligibility criteria
Healthy men aged 18 to 55 years
Exclusion of recent radiation exposure
Treatment
Single dose of carbon-14-labeled varegacestat as two oral capsules after an overnight fast
Study outcomes
Rationale for using mass balance recovery as the primary endpoint
Secondary endpoints: total radioactivity, pharmacokinetics, metabolite profile, and safety
Statistical analysis description
Number of participants (Planned and analyzed)
Actual enrollment
| Study characteristic | Quoted record |
|---|---|
| Enrollment (actual) | “6” |
Description of analysis sets
No evidence found.
Results
Participant disposition
No evidence found.
Baseline characteristics
No evidence found.
Efficacy results
No evidence found.
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
No evidence found.
Study limitations
Summary
- AL102-504 is known only from its registry record. The record lists the study as “Completed”, with primary completion on 2025-03-11, and shows no posted results; no publication, congress presentation, or Immunome document reporting its results was identified, so the routes of elimination and the metabolite profile of varegacestat are unknown from public sources.
- The study enrolled 6 healthy men aged 18 to 55 years and gave a single dose of approximately 100 µCi of [14C]varegacestat, so it provides no data in women, in patients with desmoid tumors, or at steady state.
VAR-505
Objective
Relative bioavailability and bioequivalence of capsule formulations
Location and study date
Registry status, dates, and site
| Study characteristic | Quoted record |
|---|---|
| Protocol number | “VAR-505” |
| Sponsor | “Immunome, Inc.” |
| Overall status | “Recruiting” |
| Study start (actual) | “2026-05-21” |
| Primary completion (estimated) | “2027-05” |
| Study completion (estimated) | “2027-05” |
| First posted | “2026-05-27” |
| Last update posted | “2026-10-29” |
| Site | “Celerion, Inc.”; “Tempe” |
Study design
Randomized, open-label, two-part crossover
| Study characteristic | Quoted record |
|---|---|
| Phase | “Phase 1” |
| Allocation | “Randomized” |
| Intervention model | “Crossover Assignment” |
| Masking | “None (Open Label)” |
| Primary purpose | “Other” |
| Part 1 sequences | “Part 1: Reference Formulation, then Test Formulation A”; “Part 1: Test Formulation A, then Reference Formulation” |
| Part 2 sequences | “Part 2: Reference Formulation, then Test Formulation B”; “Part 2: Test Formulation B, then Reference Formulation”; “Part 2: Reference Formulation, then Test Formulation C”; “Part 2: Test Formulation C, then Reference Formulation” |
Eligibility criteria
Healthy nonsmoking adults aged 18 to 55 years
Treatment
Oral reference and test formulations
| Intervention | Quoted record |
|---|---|
| Reference | “Varegacestat Reference Formulation” |
| Test formulations | “Varegacestat Test Formulation A”; “Varegacestat Test Formulation B”; “Varegacestat Test Formulation C” |
| Route | “Oral administration” |
Study outcomes
Rationale for using pharmacokinetic parameters as the primary endpoint
Primary endpoints: relative bioavailability by AUC and Cmax
Secondary endpoints: safety and tolerability
Statistical analysis description
Number of participants (Planned and analyzed)
Estimated enrollment
| Study characteristic | Quoted record |
|---|---|
| Enrollment (estimated) | “44” |
Description of analysis sets
No evidence found.
Results
Participant disposition
No evidence found.
Baseline characteristics
No evidence found.
Efficacy results
No evidence found.
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
No evidence found.
Study limitations
Summary
- VAR-505 is known only from its registry record. The record lists the study as “Recruiting”, with an actual start on 2026-05-21 and estimated primary completion in 2027-05, and no results are available.
- The registry record names a reference formulation and test formulations A, B, and C without stating their strengths or composition, so the relationship between the test capsules and the capsules used in RINGSIDE or proposed for marketing cannot be determined from the record.
- The study enrolls healthy adults aged 18 to 55 years under fasting conditions, with an estimated enrollment of 44 participants.